Cue Biopharma
Clinical trials sponsored by Cue Biopharma, explained in plain language.
-
New hope for HPV+ head and neck cancer: experimental drug CUE-101 tested
Disease control CompletedThis early-phase study tested a new drug called CUE-101, alone or with pembrolizumab, in 80 adults with HPV16-positive head and neck cancer that had spread or returned. The main goals were to check safety and find the right dose. Researchers also looked at whether the drug helped…
Phase: PHASE1 • Sponsor: Cue Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New Immune-Targeting drug tested for stubborn cancers
Disease control CompletedThis early-phase trial tested a new drug called CUE-102 in 42 adults with certain advanced cancers (colorectal, gastric, pancreatic, or ovarian) that had returned or spread despite prior treatments. The drug is designed to help the immune system attack cancer cells that carry a s…
Phase: PHASE1 • Sponsor: Cue Biopharma • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC